The study found that lenalidomide and pomalidomide prevented MHC-I downregulation during viral lytic activation, and restored ICAM-1 and B7-2 expression on the PEL cell surface in the viral latent infection state [84]. Here, ICAM1 is linked to disease arising from reactivation of latent virus.